Skip to content

Neuronetics STIM Net Investment in Lease

Net Investment in Lease at other companies

LifeStance Health Group logo
LifeStance Health GroupLFST
LBR
LB Pharmaceuticals Inc Common StockLBRX
CVRx, Inc. logo
CVRx, Inc.CVRX
Stereotaxis logo
StereotaxisSTXS
Neuropace, Inc. logo
Neuropace, Inc.NPCE
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$34.5M+7.8%
Gross profit$16.2M+2.6%
Operating income-$9.0M+18.3%
Net income-$10.8M+14.9%
EPS (diluted)-$0.16+23.8%

Balance sheet

See full
Cash & equivalents$13.2M-34.7%
Total debt$85.4M+3.5%
Total equity$13.3M-62.6%
Total assets$125.4M-11.7%

Cash flow

See full
Operating cash flow-$9.4M+44.6%
CapEx$197.0K-10.0%
Free cash flow-$9.6M+44.1%

Valuation

See full
Market cap$90.46M-56.2%
Enterprise value$162.64M-42.0%
P/S0.6×-1.3×

Profitability

See full
Gross margin48%-15.6pp
Operating margin-19.4%-6.9pp
Net margin-24.5%-8.7pp
FCF margin-9.4%-4.1pp

Returns & leverage

See full
Return on equity-152.4%-1.4pp
Debt / equity6.4×+4.1×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Neuronetics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Neuronetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuronetics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neuronetics's net investment in lease?
Neuronetics (STIM) reported net investment in lease of $23.07M in Q1 2026.
How has Neuronetics's net investment in lease changed year-over-year?
Neuronetics's net investment in lease decreased by 13.6% year-over-year, from $26.7M to $23.07M.
What is the long-term trend for Neuronetics's net investment in lease?
Over 5 years (2020 to 2025), Neuronetics's net investment in lease has grown at a 47.1% compound annual growth rate (CAGR), from $3.42M to $23.56M.